Patent
US 10,471,199GRAPHENE-BASED FILTER FOR ISOLATING A SUBSTANCE FROM BLOOD
Svetlana Monakhova Bachmann
US
Copyright © 2026 Matter42. All rights reserved.
Patent
Atlas literature
Patent
US 10,471,199Patent drawings and their descriptions. Click a drawing to enlarge it.
FIG. 1 is a conceptual diagram illustrating substances dissolved or suspended in the blood stream. Atty. Dkt. No. 111423-132 1 CON [0014]
FIG. 2 is a conceptual diagram illustrating an example of two stage bypass filtering according to techniques described in this disclosure. [0015]
FIG. 3 is a conceptual diagram illustrating a cross-sectional view of a filter according to techniques of this disclosure. [0016]
FIG. 4 is a conceptual diagram illustrating a cross-sectional view of a filter according to techniques of this disclosure. [0017]
FIG. 5 is a conceptual diagram illustrating an example device for isolating a substance from a solution according to techniques of this disclosure. [0018]
FIG. 6 is a conceptual diagram illustrating an example device for isolating a substance from a solution according to techniques of this disclosure. [0019]
FIG. 7 is a conceptual diagram illustrating an example device for isolating a substance from blood affixed to a patient. [0020]
FIG. 8 is a conceptual diagram illustrating an example device for isolating a substance from blood affixed to a patient.
Claims define the patent's legal scope. Independent claims stand alone; dependent claims (nested) narrow them. Click a claim to expand its dependents.
-20. Canceled
Canceled
A method for treating diabetes, the method comprising: implanting into a subject in need thereof a device comprising-a first graphene sheet, wherein the first graphene sheet comprises a first plurality of apertures having an effective diameter that allows passage of glucose through the first graphene sheet, a second graphene sheet comprising a second plurality of apertures,[[,]] and a conduit system operably coupled to the first graphene sheet and the second graphene sheet, wherein the conduit system is configured to isolate glucose, wherein the device is effective for lowering the amount of glucose in [[the]] a bloodstream. Currently amended
The method of claim 21, wherein the first plurality of apertures comprises apertures with a nominal diameter of at least 0.74 nm and 2-3% larger than the effective diameter of glucose. Currently amended
The method of claim 21, wherein the first plurality of apertures comprises apertures that are nominally spaced 2 nanometers center-to-center. Currently amended
The method of claim 21, wherein the device is configured to allow blood to cross the first graphene sheet and the second graphene sheet. Currently amended
The method of claim 21, further comprising circulating blood through the first graphene sheet and the second graphene sheet. Currently amended
The method of claim 21, wherein the glucose in the bloodstream is lowered by non-hormonal means. Previously presented
Canceled
A device for isolating glucose from blood, wherein the device comprises a graphene sheet comprising a plurality of apertures, wherein the plurality of apertures comprises apertures with an effective diameter that (i) allows passage of the glucose through the graphene sheet and (ii) prevents passage of some blood constituents through the graphene sheet, wherein the plurality of apertures comprises apertures with a nominal diameter of at least 0.74 nm, and wherein the device is configured to allow blood to circulate through the graphene sheet. Withdrawn
The device of claim 28, wherein the plurality of apertures comprises apertures that are nominally spaced 2 nanometers center-to-center. Withdrawn
The device of claim 28, wherein the device further comprises a means for lowering the amount of glucose in the bloodstream. Withdrawn
The device of claim 28, wherein the device comprises multiple graphene sheets, each with a plurality of apertures. Withdrawn
An implantable medical device for the treatment of diabetes, the implantable medical device comprising: at least one layer of graphene; a plurality of apertures perforated into the at least one layer of graphene, wherein the apertures have an effective diameter sufficient to prevent the passage of certain constituents of blood through the at least one layer of graphene to treat diabetes while permitting the passage of certain other constituents of blood, and wherein the apertures have a spacing so as to provide a sufficient flow rate while maintaining a required level of strength to avoid rupture of the at least one layer of graphene. Withdrawn
The implantable medical device of claim 32, wherein the at least one layer of graphene is positioned in the presence of blood and constituents of blood. Withdrawn
The implantable medical device of claim 32, wherein the plurality of apertures comprises apertures with a nominal diameter of at least 0.74 nm. Withdrawn
The implantable medical device of claim 32, wherein the plurality of apertures comprises apertures that are nominally spaced 2 nanometers center-to-center. Withdrawn
The implantable medical device of claim 32, wherein the device comprises multiple graphene sheets, each with a plurality of apertures. Withdrawn
The implantable medical device of claim 32, wherein glucose is able to pass through the at least one layer of graphene. Withdrawn
A method for isolating blood constituents, the method comprising: passing blood through a first graphene sheet comprising a first plurality of apertures and a second graphene sheet comprising a second plurality of apertures, wherein the first plurality of apertures and the second plurality of apertures comprise apertures with an effective diameter that allows passage of the blood constituents through the first graphene sheet and the second graphene sheet to thereby isolate the blood constituents from the blood wherein a conduit system is operably coupled to the first graphene sheet and the second graphene sheet, wherein the conduit system is configured to isolate glucose, and wherein the blood constituents comprise glucose. Currently amended
The method of claim 38, wherein the first plurality of apertures comprises apertures with a nominal diameter of at least 0.74 nm and 2-3% larger than the effective diameter of glucose. Currently amended
The method of claim 38, wherein the first plurality of apertures comprises apertures that are nominally spaced 2 nanometers center-to-center. Currently amended
The method of claim 38, wherein [[the]] a circulatory system circulates blood through the first graphene sheet and the second graphene sheet. Currently amended
The method of claim 38, wherein the method lowers the amount of glucose in the bloodstream of a subject. Previously presented
The method of claim 38, where the blood constituents further comprise one or more of sucrose, polyethylene glycol, inulin, myoglobin, lysozyme, lactoglobulin, egg albumin, hemoglobin, and serum albumin. Previously presented
The method of claim 38, further comprising returning at least some of the isolated blood constituents to the blood. Previously presented
The method of claim 38, wherein the first graphene sheet and the second graphene sheet [[is]]are a part of a medical device implanted in a subject. Currently amended
Canceled
Layer stacks claimed or described, ordered top of device to substrate.
graphene-based dual-sheet implantable filter device for diabetes treatment
graphene-based single-sheet device for isolating glucose from blood
implantable medical device for treatment of diabetes with perforated graphene layer(s)
Materials described outside the worked examples.
graphene
glucose
C₆H₁₂O₆
Performance values and ranges asserted in the specification or claims.
| Property | Value | Material |
|---|---|---|
Thickness | ≥ 0.74 nm | — |
Patent
Atlas literature
Patent
US 10,471,199Patent drawings and their descriptions. Click a drawing to enlarge it.
FIG. 1 is a conceptual diagram illustrating substances dissolved or suspended in the blood stream. Atty. Dkt. No. 111423-132 1 CON [0014]
FIG. 2 is a conceptual diagram illustrating an example of two stage bypass filtering according to techniques described in this disclosure. [0015]
FIG. 3 is a conceptual diagram illustrating a cross-sectional view of a filter according to techniques of this disclosure. [0016]
FIG. 4 is a conceptual diagram illustrating a cross-sectional view of a filter according to techniques of this disclosure. [0017]
FIG. 5 is a conceptual diagram illustrating an example device for isolating a substance from a solution according to techniques of this disclosure. [0018]
FIG. 6 is a conceptual diagram illustrating an example device for isolating a substance from a solution according to techniques of this disclosure. [0019]
FIG. 7 is a conceptual diagram illustrating an example device for isolating a substance from blood affixed to a patient. [0020]
FIG. 8 is a conceptual diagram illustrating an example device for isolating a substance from blood affixed to a patient.
Claims define the patent's legal scope. Independent claims stand alone; dependent claims (nested) narrow them. Click a claim to expand its dependents.
-20. Canceled
Canceled
A method for treating diabetes, the method comprising: implanting into a subject in need thereof a device comprising-a first graphene sheet, wherein the first graphene sheet comprises a first plurality of apertures having an effective diameter that allows passage of glucose through the first graphene sheet, a second graphene sheet comprising a second plurality of apertures,[[,]] and a conduit system operably coupled to the first graphene sheet and the second graphene sheet, wherein the conduit system is configured to isolate glucose, wherein the device is effective for lowering the amount of glucose in [[the]] a bloodstream. Currently amended
The method of claim 21, wherein the first plurality of apertures comprises apertures with a nominal diameter of at least 0.74 nm and 2-3% larger than the effective diameter of glucose. Currently amended
The method of claim 21, wherein the first plurality of apertures comprises apertures that are nominally spaced 2 nanometers center-to-center. Currently amended
The method of claim 21, wherein the device is configured to allow blood to cross the first graphene sheet and the second graphene sheet. Currently amended
The method of claim 21, further comprising circulating blood through the first graphene sheet and the second graphene sheet. Currently amended
The method of claim 21, wherein the glucose in the bloodstream is lowered by non-hormonal means. Previously presented
Canceled
A device for isolating glucose from blood, wherein the device comprises a graphene sheet comprising a plurality of apertures, wherein the plurality of apertures comprises apertures with an effective diameter that (i) allows passage of the glucose through the graphene sheet and (ii) prevents passage of some blood constituents through the graphene sheet, wherein the plurality of apertures comprises apertures with a nominal diameter of at least 0.74 nm, and wherein the device is configured to allow blood to circulate through the graphene sheet. Withdrawn
The device of claim 28, wherein the plurality of apertures comprises apertures that are nominally spaced 2 nanometers center-to-center. Withdrawn
The device of claim 28, wherein the device further comprises a means for lowering the amount of glucose in the bloodstream. Withdrawn
The device of claim 28, wherein the device comprises multiple graphene sheets, each with a plurality of apertures. Withdrawn
An implantable medical device for the treatment of diabetes, the implantable medical device comprising: at least one layer of graphene; a plurality of apertures perforated into the at least one layer of graphene, wherein the apertures have an effective diameter sufficient to prevent the passage of certain constituents of blood through the at least one layer of graphene to treat diabetes while permitting the passage of certain other constituents of blood, and wherein the apertures have a spacing so as to provide a sufficient flow rate while maintaining a required level of strength to avoid rupture of the at least one layer of graphene. Withdrawn
The implantable medical device of claim 32, wherein the at least one layer of graphene is positioned in the presence of blood and constituents of blood. Withdrawn
The implantable medical device of claim 32, wherein the plurality of apertures comprises apertures with a nominal diameter of at least 0.74 nm. Withdrawn
The implantable medical device of claim 32, wherein the plurality of apertures comprises apertures that are nominally spaced 2 nanometers center-to-center. Withdrawn
The implantable medical device of claim 32, wherein the device comprises multiple graphene sheets, each with a plurality of apertures. Withdrawn
The implantable medical device of claim 32, wherein glucose is able to pass through the at least one layer of graphene. Withdrawn
A method for isolating blood constituents, the method comprising: passing blood through a first graphene sheet comprising a first plurality of apertures and a second graphene sheet comprising a second plurality of apertures, wherein the first plurality of apertures and the second plurality of apertures comprise apertures with an effective diameter that allows passage of the blood constituents through the first graphene sheet and the second graphene sheet to thereby isolate the blood constituents from the blood wherein a conduit system is operably coupled to the first graphene sheet and the second graphene sheet, wherein the conduit system is configured to isolate glucose, and wherein the blood constituents comprise glucose. Currently amended
The method of claim 38, wherein the first plurality of apertures comprises apertures with a nominal diameter of at least 0.74 nm and 2-3% larger than the effective diameter of glucose. Currently amended
The method of claim 38, wherein the first plurality of apertures comprises apertures that are nominally spaced 2 nanometers center-to-center. Currently amended
The method of claim 38, wherein [[the]] a circulatory system circulates blood through the first graphene sheet and the second graphene sheet. Currently amended
The method of claim 38, wherein the method lowers the amount of glucose in the bloodstream of a subject. Previously presented
The method of claim 38, where the blood constituents further comprise one or more of sucrose, polyethylene glycol, inulin, myoglobin, lysozyme, lactoglobulin, egg albumin, hemoglobin, and serum albumin. Previously presented
The method of claim 38, further comprising returning at least some of the isolated blood constituents to the blood. Previously presented
The method of claim 38, wherein the first graphene sheet and the second graphene sheet [[is]]are a part of a medical device implanted in a subject. Currently amended
Canceled
Layer stacks claimed or described, ordered top of device to substrate.
graphene-based dual-sheet implantable filter device for diabetes treatment
graphene-based single-sheet device for isolating glucose from blood
implantable medical device for treatment of diabetes with perforated graphene layer(s)
Materials described outside the worked examples.
graphene
glucose
C₆H₁₂O₆
Performance values and ranges asserted in the specification or claims.
| Property | Value | Material |
|---|---|---|
Thickness | ≥ 0.74 nm | — |
Patent
Atlas literature
Patent
US 10,471,199Patent drawings and their descriptions. Click a drawing to enlarge it.
FIG. 1 is a conceptual diagram illustrating substances dissolved or suspended in the blood stream. Atty. Dkt. No. 111423-132 1 CON [0014]
FIG. 2 is a conceptual diagram illustrating an example of two stage bypass filtering according to techniques described in this disclosure. [0015]
FIG. 3 is a conceptual diagram illustrating a cross-sectional view of a filter according to techniques of this disclosure. [0016]
FIG. 4 is a conceptual diagram illustrating a cross-sectional view of a filter according to techniques of this disclosure. [0017]
FIG. 5 is a conceptual diagram illustrating an example device for isolating a substance from a solution according to techniques of this disclosure. [0018]
FIG. 6 is a conceptual diagram illustrating an example device for isolating a substance from a solution according to techniques of this disclosure. [0019]
FIG. 7 is a conceptual diagram illustrating an example device for isolating a substance from blood affixed to a patient. [0020]
FIG. 8 is a conceptual diagram illustrating an example device for isolating a substance from blood affixed to a patient.
Claims define the patent's legal scope. Independent claims stand alone; dependent claims (nested) narrow them. Click a claim to expand its dependents.
-20. Canceled
Canceled
A method for treating diabetes, the method comprising: implanting into a subject in need thereof a device comprising-a first graphene sheet, wherein the first graphene sheet comprises a first plurality of apertures having an effective diameter that allows passage of glucose through the first graphene sheet, a second graphene sheet comprising a second plurality of apertures,[[,]] and a conduit system operably coupled to the first graphene sheet and the second graphene sheet, wherein the conduit system is configured to isolate glucose, wherein the device is effective for lowering the amount of glucose in [[the]] a bloodstream. Currently amended
The method of claim 21, wherein the first plurality of apertures comprises apertures with a nominal diameter of at least 0.74 nm and 2-3% larger than the effective diameter of glucose. Currently amended
The method of claim 21, wherein the first plurality of apertures comprises apertures that are nominally spaced 2 nanometers center-to-center. Currently amended
The method of claim 21, wherein the device is configured to allow blood to cross the first graphene sheet and the second graphene sheet. Currently amended
The method of claim 21, further comprising circulating blood through the first graphene sheet and the second graphene sheet. Currently amended
The method of claim 21, wherein the glucose in the bloodstream is lowered by non-hormonal means. Previously presented
Canceled
A device for isolating glucose from blood, wherein the device comprises a graphene sheet comprising a plurality of apertures, wherein the plurality of apertures comprises apertures with an effective diameter that (i) allows passage of the glucose through the graphene sheet and (ii) prevents passage of some blood constituents through the graphene sheet, wherein the plurality of apertures comprises apertures with a nominal diameter of at least 0.74 nm, and wherein the device is configured to allow blood to circulate through the graphene sheet. Withdrawn
The device of claim 28, wherein the plurality of apertures comprises apertures that are nominally spaced 2 nanometers center-to-center. Withdrawn
The device of claim 28, wherein the device further comprises a means for lowering the amount of glucose in the bloodstream. Withdrawn
The device of claim 28, wherein the device comprises multiple graphene sheets, each with a plurality of apertures. Withdrawn
An implantable medical device for the treatment of diabetes, the implantable medical device comprising: at least one layer of graphene; a plurality of apertures perforated into the at least one layer of graphene, wherein the apertures have an effective diameter sufficient to prevent the passage of certain constituents of blood through the at least one layer of graphene to treat diabetes while permitting the passage of certain other constituents of blood, and wherein the apertures have a spacing so as to provide a sufficient flow rate while maintaining a required level of strength to avoid rupture of the at least one layer of graphene. Withdrawn
The implantable medical device of claim 32, wherein the at least one layer of graphene is positioned in the presence of blood and constituents of blood. Withdrawn
The implantable medical device of claim 32, wherein the plurality of apertures comprises apertures with a nominal diameter of at least 0.74 nm. Withdrawn
The implantable medical device of claim 32, wherein the plurality of apertures comprises apertures that are nominally spaced 2 nanometers center-to-center. Withdrawn
The implantable medical device of claim 32, wherein the device comprises multiple graphene sheets, each with a plurality of apertures. Withdrawn
The implantable medical device of claim 32, wherein glucose is able to pass through the at least one layer of graphene. Withdrawn
A method for isolating blood constituents, the method comprising: passing blood through a first graphene sheet comprising a first plurality of apertures and a second graphene sheet comprising a second plurality of apertures, wherein the first plurality of apertures and the second plurality of apertures comprise apertures with an effective diameter that allows passage of the blood constituents through the first graphene sheet and the second graphene sheet to thereby isolate the blood constituents from the blood wherein a conduit system is operably coupled to the first graphene sheet and the second graphene sheet, wherein the conduit system is configured to isolate glucose, and wherein the blood constituents comprise glucose. Currently amended
The method of claim 38, wherein the first plurality of apertures comprises apertures with a nominal diameter of at least 0.74 nm and 2-3% larger than the effective diameter of glucose. Currently amended
The method of claim 38, wherein the first plurality of apertures comprises apertures that are nominally spaced 2 nanometers center-to-center. Currently amended
The method of claim 38, wherein [[the]] a circulatory system circulates blood through the first graphene sheet and the second graphene sheet. Currently amended
The method of claim 38, wherein the method lowers the amount of glucose in the bloodstream of a subject. Previously presented
The method of claim 38, where the blood constituents further comprise one or more of sucrose, polyethylene glycol, inulin, myoglobin, lysozyme, lactoglobulin, egg albumin, hemoglobin, and serum albumin. Previously presented
The method of claim 38, further comprising returning at least some of the isolated blood constituents to the blood. Previously presented
The method of claim 38, wherein the first graphene sheet and the second graphene sheet [[is]]are a part of a medical device implanted in a subject. Currently amended
Canceled
Layer stacks claimed or described, ordered top of device to substrate.
graphene-based dual-sheet implantable filter device for diabetes treatment
graphene-based single-sheet device for isolating glucose from blood
implantable medical device for treatment of diabetes with perforated graphene layer(s)
Materials described outside the worked examples.
graphene
glucose
C₆H₁₂O₆
Performance values and ranges asserted in the specification or claims.
| Property | Value | Material |
|---|---|---|
Thickness | ≥ 0.74 nm | — |
Patent
Atlas literature
Patent
US 10,471,199Patent drawings and their descriptions. Click a drawing to enlarge it.
FIG. 1 is a conceptual diagram illustrating substances dissolved or suspended in the blood stream. Atty. Dkt. No. 111423-132 1 CON [0014]
FIG. 2 is a conceptual diagram illustrating an example of two stage bypass filtering according to techniques described in this disclosure. [0015]
FIG. 3 is a conceptual diagram illustrating a cross-sectional view of a filter according to techniques of this disclosure. [0016]
FIG. 4 is a conceptual diagram illustrating a cross-sectional view of a filter according to techniques of this disclosure. [0017]
FIG. 5 is a conceptual diagram illustrating an example device for isolating a substance from a solution according to techniques of this disclosure. [0018]
FIG. 6 is a conceptual diagram illustrating an example device for isolating a substance from a solution according to techniques of this disclosure. [0019]
FIG. 7 is a conceptual diagram illustrating an example device for isolating a substance from blood affixed to a patient. [0020]
FIG. 8 is a conceptual diagram illustrating an example device for isolating a substance from blood affixed to a patient.
Claims define the patent's legal scope. Independent claims stand alone; dependent claims (nested) narrow them. Click a claim to expand its dependents.
-20. Canceled
Canceled
A method for treating diabetes, the method comprising: implanting into a subject in need thereof a device comprising-a first graphene sheet, wherein the first graphene sheet comprises a first plurality of apertures having an effective diameter that allows passage of glucose through the first graphene sheet, a second graphene sheet comprising a second plurality of apertures,[[,]] and a conduit system operably coupled to the first graphene sheet and the second graphene sheet, wherein the conduit system is configured to isolate glucose, wherein the device is effective for lowering the amount of glucose in [[the]] a bloodstream. Currently amended
The method of claim 21, wherein the first plurality of apertures comprises apertures with a nominal diameter of at least 0.74 nm and 2-3% larger than the effective diameter of glucose. Currently amended
The method of claim 21, wherein the first plurality of apertures comprises apertures that are nominally spaced 2 nanometers center-to-center. Currently amended
The method of claim 21, wherein the device is configured to allow blood to cross the first graphene sheet and the second graphene sheet. Currently amended
The method of claim 21, further comprising circulating blood through the first graphene sheet and the second graphene sheet. Currently amended
The method of claim 21, wherein the glucose in the bloodstream is lowered by non-hormonal means. Previously presented
Canceled
A device for isolating glucose from blood, wherein the device comprises a graphene sheet comprising a plurality of apertures, wherein the plurality of apertures comprises apertures with an effective diameter that (i) allows passage of the glucose through the graphene sheet and (ii) prevents passage of some blood constituents through the graphene sheet, wherein the plurality of apertures comprises apertures with a nominal diameter of at least 0.74 nm, and wherein the device is configured to allow blood to circulate through the graphene sheet. Withdrawn
The device of claim 28, wherein the plurality of apertures comprises apertures that are nominally spaced 2 nanometers center-to-center. Withdrawn
The device of claim 28, wherein the device further comprises a means for lowering the amount of glucose in the bloodstream. Withdrawn
The device of claim 28, wherein the device comprises multiple graphene sheets, each with a plurality of apertures. Withdrawn
An implantable medical device for the treatment of diabetes, the implantable medical device comprising: at least one layer of graphene; a plurality of apertures perforated into the at least one layer of graphene, wherein the apertures have an effective diameter sufficient to prevent the passage of certain constituents of blood through the at least one layer of graphene to treat diabetes while permitting the passage of certain other constituents of blood, and wherein the apertures have a spacing so as to provide a sufficient flow rate while maintaining a required level of strength to avoid rupture of the at least one layer of graphene. Withdrawn
The implantable medical device of claim 32, wherein the at least one layer of graphene is positioned in the presence of blood and constituents of blood. Withdrawn
The implantable medical device of claim 32, wherein the plurality of apertures comprises apertures with a nominal diameter of at least 0.74 nm. Withdrawn
The implantable medical device of claim 32, wherein the plurality of apertures comprises apertures that are nominally spaced 2 nanometers center-to-center. Withdrawn
The implantable medical device of claim 32, wherein the device comprises multiple graphene sheets, each with a plurality of apertures. Withdrawn
The implantable medical device of claim 32, wherein glucose is able to pass through the at least one layer of graphene. Withdrawn
A method for isolating blood constituents, the method comprising: passing blood through a first graphene sheet comprising a first plurality of apertures and a second graphene sheet comprising a second plurality of apertures, wherein the first plurality of apertures and the second plurality of apertures comprise apertures with an effective diameter that allows passage of the blood constituents through the first graphene sheet and the second graphene sheet to thereby isolate the blood constituents from the blood wherein a conduit system is operably coupled to the first graphene sheet and the second graphene sheet, wherein the conduit system is configured to isolate glucose, and wherein the blood constituents comprise glucose. Currently amended
The method of claim 38, wherein the first plurality of apertures comprises apertures with a nominal diameter of at least 0.74 nm and 2-3% larger than the effective diameter of glucose. Currently amended
The method of claim 38, wherein the first plurality of apertures comprises apertures that are nominally spaced 2 nanometers center-to-center. Currently amended
The method of claim 38, wherein [[the]] a circulatory system circulates blood through the first graphene sheet and the second graphene sheet. Currently amended
The method of claim 38, wherein the method lowers the amount of glucose in the bloodstream of a subject. Previously presented
The method of claim 38, where the blood constituents further comprise one or more of sucrose, polyethylene glycol, inulin, myoglobin, lysozyme, lactoglobulin, egg albumin, hemoglobin, and serum albumin. Previously presented
The method of claim 38, further comprising returning at least some of the isolated blood constituents to the blood. Previously presented
The method of claim 38, wherein the first graphene sheet and the second graphene sheet [[is]]are a part of a medical device implanted in a subject. Currently amended
Canceled
Layer stacks claimed or described, ordered top of device to substrate.
graphene-based dual-sheet implantable filter device for diabetes treatment
graphene-based single-sheet device for isolating glucose from blood
implantable medical device for treatment of diabetes with perforated graphene layer(s)
Materials described outside the worked examples.
graphene
glucose
C₆H₁₂O₆
Performance values and ranges asserted in the specification or claims.
| Property | Value | Material |
|---|---|---|
Thickness | ≥ 0.74 nm | — |